参考文献/References:
[1] 祝晓雨，张伟光，赵志刚. 骨质疏松症国内外药物治疗的研究现状[J]. 中国临床药理学杂志，2020，36(5): 588-592.[2] SLEEMAN A, CLEMENTS J N. Abaloparatide: A new pharmacological option for osteoporosis[J]. American Journal of Health System Pharmacy, 2019, 76(3): 130-135.[3] DRAKE M T, CREMERS S, RUSSELL R G, et al. Drugs for the treatment of metabolic bone diseases[J]. British Journal of Clinical Pharmacology, 2019, 85(6): 1049.[4] AN J, YANG H, ZHANG Q, et al. Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation[J]. Life Sciences, 2016, 147: 46-58.[5] YU Q, SONG F J, CHEN J F, et al. Antineuroinflammatory effects of modified wu-zi-yan-zong prescription in β-amyloid-stimulated BV2 microglia via the NF-κB and ERK/p38 MAPK signaling pathways[J]. Evidence-Based Complementary and Alternative Medicine, 2017, 2017: 8470381.[6] 曹圣，热增才旦，李永平，等. 五子衍宗丸应用机理探讨[J]. 时珍国医国药，2017，28(10): 2476-2478.[7] 高云霄，刘保兴，秦茂，等. 五子衍宗丸通过增强支持细胞自噬改善生精功能[J]. 中华中医药杂志，2019，34(3): 961-964.[8] 王宁，张树成，陈西华，等. 五子衍宗丸对无精症小鼠的免疫促进作用基因表达谱分析[J]. 上海中医药大学学报，2013，27(4): 63-67.[9] 马娜，赵海霞，陈茜，等. 基于P53/P21和碱基切除修复通路的五子衍宗方对自然衰老大鼠睾丸DNA损伤的保护作用研究[J]. 中草药，2018，49(6): 1379-1384.[10] 牛丽颖，刘娇，李清，等. 五子衍宗丸对去势致骨质疏松大鼠骨形态计量学参数的影响[J]. 中药药理与临床，2008(4): 5-7.[11] LIU B, WU S, HAN L, et al. β-catenin signaling induces the osteoblastogenic differentiation of human pre-osteoblastic and bone marrow stromal cells mainly through the upregulation of osterix expression[J]. International Journal of Molecular Medicine, 2015, 36(6): 1572-1582.[12] 李春树. 膝骨关节炎患者远红外线理疗后IL-18、TNF-α的变化及其关系研究[J]. 中国疗养医学，2020，29(10): 1050-1052.[13] 朱书涛，刘洋，张明辉，等. 去卵巢大鼠骨组织中肿瘤坏死因子α、白细胞介素1β及白细胞介素6水平与骨质疏松的关系[J]. 中国组织工程研究，2016，20(15): 2206-2211.[14] DE MARTINIS M, SIRUFO M M, SUPPA M, et al. IL-33/IL-31 axis in oste-oporosis[J]. International Journal of Molecular Sciences, 2020, 21(4): 1239. [15] 罗湘杭，廖二元，周后德，等. 人成骨肉瘤MG 63细胞株和正常成人成骨细胞MMP及TIMP的表达[J]. 湖南医科大学学报，2001，26(3): 206208.[16] RIFAS L, FAUSTO A, SCOTT M J etalExpression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: differentiation is associated with repression of metalloproteinase biosynthesis[J]. Endocrinology, 1994, 134(1): 213-221.[17] MITEK T, NAGRABA U, J DESZCZY SKI, et al. Genetic predisposition for osteoporosis and fractures in postmenopausal women[J]. Advances in Experimental Medicine and Biology, 2019, 1211: 17-24.[18] 王旭红，刘改霞，李耀辉，等. 基于网络药理学探寻β-谷甾醇的作用机制[J]. 世界中医药，2022，17(2): 172-176.[19] 汪帅，孙宇，李春梅，等. 豆甾醇的研究进展概述[J].中国药业，2019，28(23): 96-98.[20] CHAUHAN S, SHARMA A, UPADHYAY NK, et al. In-vitro osteoblast proliferation and in-vivo anti-osteopo-rotic activity of Bombax ceiba with quantification of Lupeol, gallic acid and β-sitosterol by HPTLC and HPLC[J]. BMC Complementary and Alternative Medicine, 2018, 18(1): 233.[21] KIM CJ, SHIN SH, KIM BJ, et al. The effects of kaempferol-inhibited autophagy on osteoclast formation[J]. International Journal of Molecular Sciences 2018, 19(1): 125.[22] OKAZAKI K, YAMAGUCHI T, TANAKA K, et al. Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis[J]. Calcified Tissue International, 2012, 91(4): 286-296.[23] KRUM S A, BROWN M. Unraveling estrogen action in osteoporosis[J]. Cell Cycle, 2008, 7(10): 1348-1352. [24] 黄少慧，李娟，赵毅，等. 补肾中药骨灵片对人成骨细胞功能和p38活化原蛋白激酶通路的影响[J]. 热带医学杂志，2011，7(5): 418-420. [25] NAKAJIMA A, SANJAY A, CHIUSAROLI R, et al. Loss of Cblb in creases osteoclast bone-resorbing activity and induces osteopenia[J]. Journal of Bone and Mineral Research, 2009, 24(7): 1162-1172. [26] MARAHLEH A, KITAURA H, OHORI F, et al. TNF-αdirectly enhances osteocyteRANKL expression and promotes osteoclast formation[J]. Frontiers in Immunology, 2019, 10: 2925. [27] BHARTI A C, TAKADA Y, SHISHODIA S, et al. Evidence that receptor activator of nuclear factor(NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism[J]. Journal of Biological Chemistry, 2004, 279(7): 6065-6076. [28] MANSOORI M N, SHUKLA P, SINGH D. Combination of PTH(1-34) with anti-IL17 prevents bone loss by inhibiting IL-17/N-cadherin mediated disruption of PTHR1/LRP-6 interaction[J]. Bone, 2017, 105: 226-236.